Results 171 to 180 of about 5,266 (226)

PF4 activates the c-Mpl-Jak2 pathway in platelets.

Blood
Buka RJ, Montague SJ, Moran LA, Martin EM, Slater A, Watson SP, Nicolson PLR.   +6 more
europepmc   +1 more source

Pipeline embolization device as a standalone curative approach for recurrent sigmoid sinus DAVF.

Interv Neuroradiol
Sharashidze V, Chung C, Nelson PK, Shapiro M, Riina H, Nossek E, Raz E.   +6 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Delayed-onset eptifibatide-induced thrombocytopenia

American Journal of Health-System Pharmacy, 2023
Abstract Purpose We present a unique case of delayed-onset, profound eptifibatide-induced thrombocytopenia that occurred 5 days after initiation of the drug. Summary Eptifibatide is a platelet glycoprotein IIb/IIIa receptor inhibitor ...
Travis, Huffman, Evan, Gleaves, Glee, Lenoir, Rahil, Rafeedheen   +3 more
openaire   +3 more sources

Complications and Management of Eptifibatide-Induced Thrombocytopenia

Annals of Pharmacotherapy, 2021
Background Eptifibatide is used in acute coronary syndromes to reversibly block platelet aggregation by inhibiting the platelet glycoprotein IIb/IIIa receptor. A serious adverse effect of eptifibatide is a profound drop in platelet count, termed eptifibatide-induced thrombocytopenia (EIT).
Eli D. Ehrenpreis, Eli D. Ehrenpreis, Faisal Masood, Adib Chaus, Anna Hertsberg, Saad Hashmi   +5 more
openaire   +5 more sources

Eptifibatide-induced profound thrombocytopaenia: a rare complication

BMJ Case Reports, 2021
Drug-induced immune thrombocytopaenia (DITP) is a type of thrombocytopaenia caused by medications. It is one of the common causes of unexplained thrombocytopaenia. It is caused by the formation of autoantibodies against a particular drug and is commonly observed with medications like heparin and beta-lactam antibiotics.
Pranav Mahajan, Fatima Ayub, Roxana Azimi, Naveed Adoni   +3 more
openaire   +4 more sources

Adjunctive Intravenous Argatroban or Eptifibatide for Ischemic Stroke

New England Journal of Medicine
Intravenous thrombolysis is a standard treatment of acute ischemic stroke. The efficacy and safety of combining intravenous thrombolysis with argatroban (an anticoagulant agent) or eptifibatide (an antiplatelet agent) are unclear.We conducted a phase 3, three-group, adaptive, single-blind, randomized, controlled clinical trial at 57 sites in the United
Opeolu Adeoye, Joseph Broderick, Colin P. Derdeyn, James C. Grotta, William Barsan, Oladi Bentho, Scott Berry, Mauricio Concha, Iris Davis, Stacie Demel, Jordan Elm, Nina Gentile, Todd Graves, Melissa Hoffman, Josephine Huang, James Ingles, Scott Janis, Adam S. Jasne, Pooja Khatri, Steven R. Levine, Aniel Majjhoo, Peter Panagos, Arthur Pancioli, Stephanie Pizzella, Tamra Ranasinghe, Noor Sabagha, Sanjeev Sivakumar, Christopher Streib, Achala Vagal, Alastair Wilson, Max Wintermark, Albert J. Yoo, Andrew D. Barreto   +32 more
openaire   +3 more sources

Safety and efficacy of eptifibatide in acute ischemic stroke requiring extracranial carotid artery stenting.

Interventional Neuroradiology, 2023
BACKGROUND The antiplatelet management in acute ischemic stroke requiring carotid artery stenting is heterogenous, with no clear guidelines to direct management.
M. Waters, J. Vargas, A. Turk, I. Chaudry, R. Turner   +4 more
semanticscholar   +1 more source

Clinical Pharmacology of Eptifibatide

The American Journal of Cardiology, 1997
Activation of receptor function of platelet membrane glycoprotein (GP) IIb-IIIa leads to the binding of fibrinogen and is the final common pathway to platelet aggregation. Platelet aggregates provide the structural basis for coronary thrombosis, a major cause of ischemic heart disease.
David R. Phillips, Robert M. Scarborough
openaire   +3 more sources

Eptifibatide-induced thrombocytopenia

Journal of Thrombosis and Thrombolysis, 2007
Glycoprotein (GP) IIb/IIIa inhibitors reduce major adverse coronary events in patients with acute coronary syndromes undergoing percutaneous coronary interventions (PCI). Unlike the other GPIIb/IIIa inhibitors, eptifibatide is rarely associated with thrombocytopenia with only a few cases reported in the medical literature. Here we report a case of a 34-
A.J. Conrad Smith, Marwan M. Refaat, Daniel Edmundowicz   +2 more
openaire   +3 more sources